stockrow
Saturday 7 November 2026
Export PHAR’s income statement to Excel — free account
Pharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.
- Revenue
- +20.9%
- EPS
- +190.9%
- Free cash flow
- +0.42%
- Total debt
- +1.61%
Quarter to September 2026, against a year earlier
12.32
0.02
+0.16%
Follow PHAR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
27.75 | 92.60 | 87.58 | 441.75 |
+8 more quarters Free account |
P/S ratio |
1.81 | 2.02 | 3.35 | 3.24 | |
P/FCF ratio |
20.27 | 21.56 | 22.24 | 22.56 | |
P/Operating CF |
21.60 | (76.70) | 634.83 | 113.67 | |
P/B ratio |
2.40 | 2.74 | 4.61 | 4.39 | |
Price to Tangible BV |
4.22 | 5.20 | 8.98 | 8.60 | |
EV/Sales |
1.58 | 1.86 | 3.16 | 3.02 | |
EV/EBITDA |
13.72 | 22.26 | 29.38 | 30.63 | |
EV/Operating CF |
17.24 | 19.42 | 20.68 | 20.75 | |
EV/FCF |
17.67 | 19.80 | 20.95 | 21.04 | |
Quick Ratio |
2.65 | 2.31 | 2.06 | 2.03 | |
Current Ratio |
3.23 | 3.01 | 2.63 | 2.59 | |
Net Debt/EBITDA |
(2.77) | (13.93) | 40.19 | (8.62) | |
Debt/Assets |
20.12% | 20.91% | 20.18% | 19.61% | |
Debt/Equity |
0.34 | 0.36 | 0.37 | 0.35 | |
Asset Turnover |
0.80 | 0.80 | 0.83 | 0.84 | |
Operating CF/Net income |
1.45 | (6.04) | (0.37) | 1.96 | |
Capex/Depreciation |
(0.11) | (0.03) | (0.08) | (0.08) | |
Research and Development Expense of Revenue |
25.17% | 35.81% | 35.28% | 30.15% | |
Selling, General and Administrative Expense of Revenue |
38.35% | 48.23% | 62.85% | 48.15% | |
Intangible Assets out of Total Assets |
0.25 | 0.27 | 0.27 | 0.27 | |
Share Based Compensation of Revenue |
1.51% | 3.71% | 4.45% | 4.23% | |
Graham Net Nets |
0.17 | 0.11 | 0.06 | 0.06 | |
Graham Number |
5.81 | 4.14 | 3.93 | 1.90 | |
Earnings Yield |
3.60% | 1.08% | 1.14% | 0.23% | |
Free Cash Flow Yield |
4.93% | 4.64% | 4.50% | 4.43% | |
Revenue per Share |
1.68 | 1.69 | 0.97 | 1.55 | |
Operating CF per Share |
0.46 | (0.18) | 0.03 | 0.16 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.46 | (0.18) | 0.02 | 0.15 | |
Cash per Share |
2.71 | 2.97 | 2.29 | 2.61 | |
Shareholders Equity per Share |
4.16 | 5.07 | 3.61 | 4.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.16 | 5.07 | 3.61 | 4.02 | |
Free Cash Flow |
32.09 | (9.74) | 1.71 | 10.44 | |
Working Capital |
222.43 | 187.44 | 183.17 | 183.68 | |
Capital Expenditures |
(0.28) | (0.08) | (0.24) | (0.27) | |
Net Current Asset Value |
116.98 | 83.20 | 75.11 | 76.61 | |
EV/EBIT |
18.77 | 36.83 | 41.72 | 43.93 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
21.53 | 40.10 | 44.30 | 47.10 | |
| Other line items | |||||
Average Receivables |
59.22 | 55.15 | 53.76 | 54.76 | |
Average Payables |
84.15 | 80.35 | 86.14 | 86.26 | |
Average Inventory |
62.56 | 64.57 | 61.96 | 60.31 | |
Average Assets |
485.21 | 457.12 | 446.27 | 449.97 | |
Average Common Equity |
277.94 | 255.02 | 242.13 | 249.08 |
Columns are period end dates · fundamentals updated 2 Nov 2026